A R T I C L E S
Deng et al.
Scheme 1. PNP-Catalyzed Reaction and lmmH-Phosphate
Interactions in the PNP‚lmmH‚PO4 Complex
in the active site might be expected. Previous studies have shown
that bovine PNP catalyzes the hydrolysis of inosine in the
absence of PO4 and binds tightly to the hypoxanthine (Kd ∼ 2
pM) product,14 supporting the formation of a ribooxacarbenium
ion and its subsequent hydrolysis. However, the observation of
stable inosine in the crystal structures of a PNP‚inosine complex
seems to be inconsistent with the SN1-like mechanism and in
favor of a SN2-like mechanism.15 The recent transition state
analysis of human PNP provides unequivocal evidence that the
arsenolysis reaction catalyzed by PNP has a transition state
closely related to a fully dissociated ribooxacarbenium ion.16
Vibrational spectroscopy is an ideal tool to probe the
electronic state of enzyme-bound phosphate and its interactions
with proteins.4,17-21 Activation of phosphate in a transition state
analogue complex of PNP‚ImmH‚PO4 has been studied by
vibrational spectroscopy and ab initio normal mode analysis.9
To investigate how PNP may activate the phosphate nucleophile
in the ground state, we have extended our vibrational studies
to the PNP‚PO4 and PNP‚R1P complexes. Our results show that
the phosphate dianions in both complexes are noticeably
distorted upon binding to PNP, established by significant
frequency changes in the phosphate P-O stretch modes.
Furthermore, we have found that bound R1P is slowly hydro-
lyzed to ribose and phosphate by attack of the water (hydroxyl)
nucleophile at C1 of R1P, rather than at the phosphorus atom.
This reaction resembles the PNP-catalyzed nucleoside synthesis
reaction. Thus, activation of the substrate R1P toward the
ribooxacarbenium ion in the PNP‚R1P complex is evidence for
the ground state activation expected in the electrophile migration
mechanism. Substrate activation arises from the unfavorable
interactions on the phosphate moiety of PNP-bound R1P
compared to either PNP-bound phosphate or R1P in solution.
causes a T-cell immunodeficiency due to dGTP accumulation
in dividing T-cells.10 Inhibition of PNP inhibits the growth of
activated T-cells, providing a clinical means to ameliorate T-cell
proliferative disorders.11 The catalytic acceleration of PNP is
achieved through formation of a transition state with oxacar-
benium ion character and specific leaving group interactions to
the purine. Ribosides with better leaving groups, such as
4-nitrophenyl-â-D-riboside, are poor substrates, establishing
leaving group activation as a major catalytic interaction.12
Catalytic site contacts to the purine fix it in one position through
the reaction coordinate and facilitate ribosyl electrophile migra-
tion from the leaving group to a phosphorus nucleophile also
immobilized at the catalytic site.7 Although the reaction equi-
librium favors nucleoside synthesis, the enzyme operates in the
phosphorolysis direction in vivo because of the rapid metabolic
removal of products by purine phosphoribosyl transferases.
Recently, nucleophilic displacement by electrophilic migration
has been proposed for PNP, hypoxanthine-guanine (-xanthine)
phosphoribosyl transferase, lysozyme, and uracil DNA glyco-
sylase.7,13 Key features of this SN1 reaction mechanism include
(1) activation of both leaving group and nucleophile, (2)
activation of the nucleobase leaving group by protonation or
by hydrogen bonding to N7, (3) formation of a fully dissociated
ribooxacarbenium ion at some point (not necessarily the
transition state) during the reaction, and (4) neighboring group
assistance by stacking the ribose O5′ over O4′ as a driving force
for the electrophile (ribooxacarbenium) migration in PNP. This
reaction mechanism is significantly different from the SN2-like
mechanisms previously proposed for a wide range of glycosyl
transferases, wherein activation of the nucleophile in the ground
state is not required and no ribooxacarbenium ion is formed.
Furthermore, the phosphate group is fixed in position relative
to the enzyme, unlike that in the PO3 transferring enzymes.
The formation of an enzyme-stabilized ribooxacarbenium ion
requires significant substrate activation in the ground state, and
hydrolytic quenching of oxacarbenium ions by water molecules
Materials and Methods
7-Methyl inosine was obtained from Sigma. H3P18O4 was prepared
according to the published procedure.22 R1P or 18O4-labeled R1P was
prepared by mixing PO4 or P18O4 and 7-methyl inosine in a 1:1.5 molar
ratio at pH 7.5 in the presence of PNP. After completion of the reaction,
the unreacted nucleoside and base were removed by charcoal. The final
products were checked by 1H and 31P NMR to be >99% pure and free
of inorganic phosphate. Human PNP was prepared as described
previously.23 To remove tightly bound hypoxanthine that co-purifies
with human PNP, the enzyme (at concentration <1 mg/mL, determined
by UV using an extinction coefficient of 30 mM-1 cm-1 at 280 nm)
was dialyzed for 3 days against 50 mM phosphate buffer at pH 7.2, 4
°C in the presence of 2 g of charcoal in the dialysate. Removal of
bound hypoxanthine was verified with proton NMR.24 Hypoxanthine-
(14) Kline, P. C.; Schramm, V. L. Biochemistry 1992, 31, 5964-73.
(15) Canduri, F.; dos Santos, D. M.; Silva, R. G.; Mendes, M. A.; Basso, L. A.;
Palma, M. S.; de Azevedo, W. F.; Santos, D. S. Biochem. Biophys. Res.
Commun. 2004, 313, 907-14.
(16) Lewandowicz, A.; Schramm, V. L. Biochemistry 2004, 43, 1458-68.
(17) Mertz, E. L.; Leikin, S. Biochemistry 2004, 43, 14901-12.
(18) Martinez-Liarte, J. H.; Iriarte, A.; Martinez-Carrion, M. Biochemistry 1992,
31, 2712-19.
(19) Wang, J. H.; Xiao, D. G.; Deng, H.; Webb, M. R.; Callender, R.
Biochemistry 1998, 37, 11106-16.
(20) Cheng, H.; Sukal, S.; Deng, H.; Leyh, T. S.; Callender, R. Biochemistry
2001, 40, 4035-43.
(10) Stoeckler, J. D. Developments in Cancer Chemotherapy. In DeVelopments
in Cancer Chemotherapy; Glazer, R. J., Ed.; CRC Press Inc.: Boca Raton,
FL, 1984; pp 35-60.
(11) Bzowska, A.; Kulikowska, E.; Shugar, D. Pharma. Ther. 2000, 88, 349-
425.
(12) Mazzella, L. J.; Parkin, D. W.; Tyler, P. C.; Furneaux, R. H.; Schramm,
V. L. J. Am. Chem. Soc. 1996, 118, 2111-2.
(13) Schramm, V. L.; Grubmeyer, C. Prog. Nucleic Acid Res. Mol. Biol. 2004,
78, 261-304.
(21) Chakrabarti, P. P.; Suveyzdis, Y.; Wittinghofer, A.; Gerwert, K. J. Biol.
Chem. 2004, 279, 46226-33.
(22) Deng, H.; Wang, J.; Ray, W. J.; Callender, R. J. Phys. Chem. B 1998, 102,
3617-23.
(23) Deng, H.; Lewandowicz, A.; Cahill, S. M.; Furneaux, R. H.; Tyler, P. C.;
Girvin, M. E.; Callender, R. H.; Schramm, V. L. Biochemistry 2004, 43,
1980-7.
(24) Deng, H.; Cahill, S. M.; Abad, J. L.; Lewandowicz, A.; Callender, R. H.;
Schramm, V. L.; Jones, R. A. Biochemistry 2004, 43, 15966-74.
9
7766 J. AM. CHEM. SOC. VOL. 128, NO. 24, 2006